Current Report Filing (8-k)
April 24 2019 - 08:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 24, 2019
ARCH THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
000-54986
|
|
46-0524102
|
(State or other jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
235 Walnut Street, Suite 6
|
|
Framingham, Massachusetts
|
01702
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(617) 431-2313
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 7.01
|
Regulation FD Disclosure.
|
On April 24, 2019, Arch Therapeutics, Inc. (the “
Company
”)
issued a press release announced that the Company will attend The Symposium on Advanced Wound Care Spring (“
SAWC”
)
from May 7-11 in San Antonio, TX and that a video demonstration of AC5
TM
Topical Gel produced for the SAWC conference
has become available for viewing. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference
herein.
The disclosure under Item 7.01 (Regulation FD Disclosure) is
incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) The following exhibits are being filed
herewith:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ARCH THERAPEUTICS, INC.
|
|
|
|
|
Dated: April 24, 2019
|
By:
|
/s/ Terrence W. Norchi, M.D.
|
|
|
Name: Terrence W. Norchi, M.D.
|
|
|
Title: President, Chief Executive Officer
|
|
|
|
|
|
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Mar 2023 to Mar 2024